Search

Fluvoxamine

Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. … It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.

Axitinib

[A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations. … It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative.

Sulfapyridine

Antibacterial, potentially toxic, and previously used to treat certain skin diseases. No longer prescribed.

Alglucerase

Alglucerase was first approved by the FDA in 1991;[A254816] however, it was later discontinued from the market. … Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase.

Diphemanil

Nicergoline

An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It has been suggested to ameliorate cognitive deficits in cerebrovascular disease.

p-Phenylenediamine

alpha-Lactalbumin

alpha-Lactalbumin is under investigation in clinical trial NCT02082418 (Effects of Alpha-lactalbumin Intake on Metabolic and Cognitive Functions in Elderly).

Mesoridazine

A phenothiazine antipsychotic with effects similar to chlorpromazine.

Lyme disease vaccine (recombinant OspA)

Lipoprotein OspA is a single polypeptide chain of 257 amino acids with lipids covalently bonded to the N terminus. It is conjugated with alum (aluminum hydroxide) as an adjuvant.